Welcome to Our Parkinson's Place
I copy news articles pertaining to research, news and information for Parkinson's disease, Dementia, the Brain, Depression and Parkinson's with Dystonia. I also post about Fundraising for Parkinson's disease and events. I try to be up-to-date as possible. I have Parkinson's diseases as well and thought it would be nice to have a place where updated news is in one place. That is why I began this blog.
I am not responsible for it's contents, I am just a copier of information searched on the computer. Please understand the copies are just that, copies and at times, I am unable to enlarge the wording or keep it uniformed as I wish. This is for you to read and to always keep an open mind.
Please discuss this with your doctor, should you have any questions, or concerns. Never do anything without talking to your doctor. I do not make any money from this website. I volunteer my time to help all of us to be informed. Please no advertisers. This is a free site for all.
Saturday, October 3, 2015
From Michael J. Fox Foundation.
Thursday, October 1, 2015
The percentage of Parkinson’s sufferers in these farming communities is 37-54 percent higher than the average in the Negev.
|Thai workers tending a farm in Israel. Eliyahu Hershkovitz|
An Israeli study has found a high incidence of Parkinson’s disease among those living in Jewish agricultural communities near the Gaza border.
According to the study, the percentage of Parkinson’s sufferers is 37 percent to 54 percent higher than the average in the Negev. The researchers, neurologists from the Soroka Medical Center in Be’er Sheva, believe that the reason for the high morbidity is exposure to pesticides, which are used in the cultivated fields.
Parkinson’s is a gradual degenerative disease that affects the central nervous system, and is characterized by motor disturbances such as a slowing and decline in movement, muscle rigidity, involuntary tremors, problems of balance and more. The source of the illness is defective functioning in the parts of the brain responsible for motor control. There is no certainty about the causes, but the prevailing assumption is that they are genetic as well as environmental.
This is not the first time that a connection has been made between exposure to pesticides and a higher incidence of Parkinson’s.
“Our study joins studies that reinforce the environmental connection to Parkinson’s, and we believe there’s a connection between agricultural pesticides and the disease,” says Dr. Yair Zlotnik of the Soroka neurology department, one of the researchers.
The present study uses the database of Parkinson’s patients in the area of the Gaza envelope who are insured by Clalit Health Services (which insures 70 percent of the Negev population), and included 3,792 patients, Jews and Bedouin, some living in cities or communal settlements and some in agricultural communities and in the Bedouin diaspora. The information was examined relative to the proximity of the patients to cultivated fields in their area of residence.
There were dramatic differences in the frequency of the disease – among Jews the percentage of Parkinson’s sufferers is 37 percent higher than the average in the Negev in places with few cultivated fields. In communities with many cultivated fields the morbidity is 54 percent higher than the regional average. In the Bedouin diaspora the frequency is 53 percent lower than the average in the Negev as a whole, and 71 percent lower than the average in the permanent communities that are not surrounded by cultivated fields.
“The study enabled us to see clearly the differences between the genetic and environmental contribution,” explained Zlotnik. “We know that in the Ashkenazi Jewish population [originating in Europe] there are a number of genes that increase the risk of the disease, and morbidity among Ashkenazim is in fact higher in general. Among the Bedouin, who have no genetic tendency for the disease, we discovered that those living in the Bedouin diaspora near agricultural fields suffer more from Parkinson’s than those living in permanent communities.”
The study is actually a continuation of one conducted in Soroka in the late 1990s. At the time they examined three kibbutzim in the Gaza envelope area and found a high incidence. Due to improved technology and documentation since then the present study is more precise and more comprehensive.
But still the study has shortcomings – it doesn’t measure morbidity in connection with specific types of pesticides. “We assume that the morbidity that we’re seeing today is a result of degenerative processes that began 20-30 years ago, and it’s hard to know today exactly to which substances they were exposed,” says Zlotnik.
Nor did the researchers take into account the residential history of the patients in the area, or in other words, for how long they were exposed to the pesticides in the Gaza area. “There’s still a lot to study regarding this connection,” explains Zlotnik. “We think that there’s room for follow-up studies, maybe together with the Environmental Protection Ministry, in order to study the nature of the exposure and its effects in greater depth.”
Wednesday, September 30, 2015
Potential breakthrough treatment for Parkinson's Disease - Story | 4State Area - Maryland, Pennsylvania, Virginia and West Virginia | Your4State | WHAG-TV
Potential breakthrough treatment for Parkinson's Disease - Story | 4State Area - Maryland, Pennsylvania, Virginia and West Virginia | Your4State | WHAG-
Potential breakthrough treatment for Parkinson's Disease
Patient from Frederick says the treatment turned back the clock for her
Monday, September 28, 2015
Scientific American presents Everyday Einstein by Quick & Dirty Tips. Scientific American and Quick & Dirty Tips are both Macmillan companies.
When award-winning science journalist Jon Palfreman investigated a group of drug addicts who mysteriously ended up with Parkinson's-like symptoms after a bad batch of heroin—the story that would end up launching his career—he never imagined that more than 25 years later he would be diagnosed with the disease himself. Today there are roughly 1 million Americans living with Parkinson’s and about 60,000 new cases each year. In this interview, Jon discusses his new book, Brain Storms: The Race to Unlock the Mysteries of Parkinson's Disease, detailing the scientific history of a search for a cure, as well as his own experience with Parkinson's.
Jon offers advice for translating the uncertainties that often come with medical advice and suggests how we can try to reconcile those odds with our need for concrete answers. He explains our best chances at beating Parkinson's, including approaches that attempt to modify the disease as well as those that work to treat the symptoms.
- Health: Researchers Seek Cancer Clues from Pet Dogs |
- Sustainability: How Modern Agriculture Can Save the Gorillas of Virunga |
- Tech: Are We on the Cusp of War—in Space? |
- The Sciences: The Mystery of the Cat's Inner Eyelid
He also offers three suggestions on how those living with Parkinson's, as well as their family and friends, can understand such a complex disease and thus offer the best support:
Have you ever had to deal with a difficult diagnosis? How did you become empowered as a patient? You can weigh on my Facebook page, or follow me on Twitter, where I’m @QDTeinstein. If you have a question that you’d like to see on a future episode, send me an email at firstname.lastname@example.org.
- See more at: http://www.quickanddirtytips.com/education/science/understanding-parkinsons-disease-an-interview-with-jon-palfreman#sthash.WBoloVq1.dpuf
Loss of smell, trouble sleeping, constipation, and shaking...Those are all signs of Parkinson's Disease.
Well September is Parkinson's Awareness Month. Those from First Settlement Physical Therapy teamed up with a local Parkinson's support group to conduct a one-day awareness event.
Community members who attended could receive information on the disease along with participating in various exercises to test their motor skills.
"Parkinson's is a really interesting disease as the people who have it have it for a prolonged period of time. So they are able to find support systems throughout their local areas and it's very helpful for them," said Amanda Schell, a Physical Therapist from First Settlement Physical Therapy.
One local man runs a support group for those with Parkinson's and to educate others about the disease. "We know the importance of movement. We are walking the side walks and just taking whatever pace we, is comfortable for us and the distance that's comfortable for each of our people," said Larry Ice who attended the event Sunday.
If anyone is interested in joining the local support group for Parkinson's Disease, they meet the second Saturday of each month at the Vienna library.
Sunday, September 27, 2015
Impax Receives Positive CHMP Opinion for NUMIENT™ (Levodopa and Carbidopa) Modified-Release Capsules for the Symptomatic Treatment of Adult Patients with Parkinson's disease
AMSTERDAM, Sept. 25, 2015 /PRNewswire/ -- Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending that NUMIENT (IPX066), a modified-release oral capsule formulation of levodopa-carbidopa, be granted approval for the symptomatic treatment of adult patients with Parkinson's disease. The European Commission (EC) will now consider the CHMP positive opinion in its decision of whether to grant marketing authorization for NUMIENT in Europe. The review of this application is being conducted under the centralized licensing procedure as a therapeutic innovation, and the final decision will be applicable in all 28 member states of the European Union, as well as Iceland, Liechtenstein and Norway.
"The positive opinion from the CHMP recommending the approval of NUMIENT is a significant step forward to providing a new treatment option to patients in Europe suffering from Parkinson's disease," said Fred Wilkinson, President and Chief Executive Officer of Impax. "We are committed to realizing the full potential of this important franchise and we look forward to the European Commission's decision in the coming months."
"We continue to have discussions with potential partners to help commercialize NUMIENT in Europe. If approved, we will work quickly to bring NUMIENT to patients," concluded Mr. Wilkinson.
The CHMP's positive opinion is based on results from three Phase 3 controlled clinical studies which assessed the safety and efficacy of NUMIENT in patients with early (levodopa-naive) and advanced Parkinson's disease in the U.S. and in Europe. Refer to the "Summary of the Three Phase 3 Controlled Clinical Studies" for additional information.
About Parkinson's disease
Parkinson's disease is a chronic neurodegenerative movement disorder affecting approximately 7 to 10 million people globally. There is currently no known cure for Parkinson's disease.
If approved in Europe, NUMIENT will be indicated for the symptomatic treatment of adult patients with Parkinson's disease. NUMIENT is not for use in patients with hypersensitivity to the active drug substances or excipients in NUMIENT, narrow-angle glaucoma, phaeochromocytoma, a previous history of neuroleptic malignant syndrome (NMS) and/or non-traumatic rhabdomyolysis, or in patients using nonselective monoamine oxidase inhibitors (MAO) inhibitors, which must be discontinued 2 weeks prior to starting to use NUMIENT.
Summary of the Three Phase 3 Controlled Clinical Studies
In APEX-PD, a trial that enrolled and randomized 381 levodopa-naive patients, the study met its primary efficacy endpoint of mean change from baseline in the sum of Unified Parkinson's Disease Rating Scale (UPDRS) Part II (activities of daily living) score and UPDRS Part III (motor examination) score for NUMIENT versus placebo at end of study.
In ADVANCE-PD, a trial of 393 randomized patients with advanced Parkinson's disease having "off" time, the results showed treatment with IPX066 (NUMIENT) reduced the percentage of "off" time (36.9% to 23.8%) from baseline versus immediate-release levodopa-carbidopa (36.0% to 29.8%) during waking hours to end of study, representing almost 1.2 hours of additional "off" time improvement. IPX066 (NUMIENT) also increased "on" time without troublesome dyskinesia during waking hours by 1.9 hours compared with an increase of 0.8 hours following treatment with immediate-release levodopa-carbidopa. Less "off" time was primarily related to more "on" time without troublesome dyskinesia.
In ASCEND-PD, a trial of 91 randomized patients with advanced Parkinson's disease having "off" time, compared IPX066 versus levodopa-carbidopa plus entacapone (LCE). Patients entered the study with a baseline "off" time of 36.1% (5.9 hours), and at the end of the randomized IPX066 treatment phase, patients had "off" time of 24.0% (3.8 hours) during waking hours compared to 32.5% (5.2 hours) for LCE (p<0.0001), representing 1.4 hours of additional "off" time improvement.
Summary of the NUMIENT Safety Profile
The most frequently reported adverse reactions in the 978 patients exposed to NUMIENT during the entire clinical program were nausea, occurring in approximately 12% of all patients; dizziness, headache, and dyskinesia, each occurring in approximately 8% of all patients; and insomnia, occurring in approximately 6% of all patients. Serious events of gastrointestinal haemorrhage (uncommon) and of allergic oedema (uncommon) were reported in the clinical studies with NUMIENT.
About Impax Laboratories, Inc.
Impax Laboratories, Inc. (Impax) is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Impax Generics division and markets its branded products through its Impax Specialty Pharma division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platforms and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995:
To the extent any statements made in this news release contain information that is not historical; these statements are forward-looking in nature and express the beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the Company's future results, performance, or achievements to differ significantly from the results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to: fluctuations in revenues and operating income; the Company's ability to successfully develop and commercialize pharmaceutical products in a timely manner; reductions or loss of business with any significant customer; the substantial portion of the Company's total revenues derived from sales of a limited number of products; the impact of consolidation of the Company's customer base; the impact of competition; the Company's ability to sustain profitability and positive cash flows; any delays or unanticipated expenses in connection with the operation of the Company's manufacturing facilities; the effect of foreign economic, political, legal, and other risks on the Company's operations abroad; the uncertainty of patent litigation and other legal proceedings; the increased government scrutiny on the Company's agreements with brand pharmaceutical companies; product development risks and the difficulty of predicting FDA filings and approvals; consumer acceptance and demand for new pharmaceutical products; the impact of market perceptions of the Company and the safety and quality of the Company's products; the Company's determinations to discontinue the manufacture and distribution of certain products; the Company's ability to achieve returns on its investments in research and development activities; changes to FDA approval requirements ; the Company's ability to successfully conduct clinical trials; the Company's reliance on third parties to conduct clinical trials and testing; the Company's lack of a license partner for commercialization of IPX066 outside of the United States; impact of illegal distribution and sale by third parties of counterfeits or stolen products; the availability of raw materials and impact of interruptions in the Company's supply chain; the Company's policies regarding returns, allowances and chargebacks; the use of controlled substances in the Company's products; the effect of current economic conditions on the Company's industry, business, results of operations and financial condition; disruptions or failures in the Company's information technology systems and network infrastructure caused by third party breaches or other events; the Company's reliance on alliance and collaboration agreements; the Company's reliance on licenses to proprietary technologies; the Company's dependence on certain employees; the Company's ability to comply with legal and regulatory requirements governing the healthcare industry; the regulatory environment; the effect of certain provisions in the Company's government contracts; the Company's ability to protect its intellectual property; exposure to product liability claims; risks relating to goodwill and intangibles; changes in tax regulations; the Company's ability to manage growth, including through potential acquisitions and investments; the integration of the acquired business of Tower Holdings, Inc. and Lineage Therapeutics Inc. by the Company being more difficult, time-consuming or costly than expected, operating costs, customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, customers, clients or suppliers) being greater than expected following the acquisition, the retention of certain key employees of the acquired business being difficult, the Company's and the acquired business's expected or targeted future financial and operating performance and results, the combined company's capacity to bring new products to market, and the possibility that the Company may be unable to achieve expected synergies and operating efficiencies in connection with the acquisition within the expected time-frames or at all, the restrictions imposed by the Company's credit facility and indenture; the Company's level of indebtedness and liabilities and the potential impact on cash flow available for operations; uncertainties involved in the preparation of the Company's financial statements; the Company's ability to maintain an effective system of internal control over financial reporting; the effect of terrorist attacks on the Company's business; the location of the Company's manufacturing and research and development facilities near earthquake fault lines; expansion of social media platforms and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission. Forward-looking statements speak only as to the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise.
 Parkinson's Disease Foundation website http://www.pdf.org/en/parkinson_statistics
Investor Relations and Corporate Communications
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/impax-receives-positive-chmp-opinion-for-numient-levodopa-and-carbidopa-modified-release-capsules-for-the-symptomatic-treatment-of-adult-patients-with-parkinsons-disease-300149147.html